SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Spherix Incorporated (formerly Biospherics Incorporated), filed for the period ended June 30, 2001. The company operates in three segments: InfoSpherix Government, InfoSpherix Commercial, and BioSpherix. The filing includes unaudited financial statements and management discussion.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 | Six Months Ended June 30, 2001 |
|---|---|---|
| Revenue | $4,840,378 | $10,058,105 |
| Net Income | $289,288 | $132,211 |
| Net Income Per Share (Diluted) | $0.03 | $0.01 |
| Cash and Cash Equivalents | $4,586,241 (as of June 30, 2001) | N/A |
| Working Capital | $6,278,000 (as of June 30, 2001) | N/A |
| Bank Line of Credit Outstanding | $1,351,394 | N/A |
| Net Cash Flow from Operations | N/A | ($1,084,379) used |
Material Changes vs. Prior Period
- Revenue: Revenue increased slightly for the three months ended June 30, 2001 ($4.84M vs. $4.68M in 2000) and remained relatively flat for the six-month period ($10.06M vs. $9.94M in 2000).
- Profitability: Net income decreased significantly year-over-year. For the six months ended June 30, 2001, net income was $132,211 compared to $1,405,338 in the same period in 2000.
- Segment Performance:
- InfoSpherix Government: Revenue increased 28% (3-month) and 58% (6-month) due to new contracts and a settlement with the U.S. Department of Labor. However, operating income for the six-month period turned negative ($12,000 loss) compared to a $65,000 loss in 2000, largely due to a $1.7M expense recognized in settlement of the labor dispute.
- InfoSpherix Commercial: Revenue declined 49% (3-month) and 67% (6-month) due to the conclusion of significant pharmaceutical contracts in the prior year.
- BioSpherix: Revenue increased 223% (3-month) driven by FlyCracker pesticide sales, though the segment continued to operate at a loss.
- Cash Flow: Operating cash flow turned negative ($1.08M used) for the six months ended June 30, 2001, compared to $1.2M provided in the prior year, primarily due to decreased net income and a significant increase in accounts receivable.
Guidance, Outlook, and Risks
- Liquidity: The company has a $1.5 million line of credit with Bank of America, with $1.35 million outstanding as of June 30, 2001. The line expires August 31, 2001, and management anticipates renewal. If not renewed, management believes current funds are adequate to meet obligations for the remainder of 2001.
- Outlook: Management expects major government contract options to be exercised, extending them beyond 2001. Royalties from the Arla Foods tagatose licensing agreement are anticipated to begin in early 2003.
- Risks: Commercial revenues are subject to substantial variation due to shorter contract terms. The company relies on the renewal of its bank line of credit. Forward-looking statements regarding future performance are subject to risks and uncertainties.
- Corporate Actions: Shareholders ratified the name change from Biospherics Incorporated to Spherix Incorporated and approved an amendment to increase the stock option plan reserve to 1,000,000 shares.
Investor Verification Checklist
- Verify the renewal status of the $1.5 million Bank of America line of credit expiring August 31, 2001.
- Confirm the collection of the $4.0 million in trade accounts receivable, which increased significantly from the prior year-end.
- Monitor the execution of contract options for InfoSpherix Government to ensure projected revenue continuity.
- Assess the commercial viability and sales trajectory of the FlyCracker product in the BioSpherix segment.
- Review the impact of the $1.7 million labor settlement expense on future government contract profitability.